Colin P.N. Dinney, MD, provides some background on translational analyses from the BOND-003 and CORE-001 trials.

The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...

For those of us who have been in the field for decades, this cycle of exhilaration or despair is common and manageable, but recent months have raised even further uncertainty about how progress in ...

Nicole A. Cipriani, explores the clinical relevance of the BRAF p.V600E mutation in papillary thyroid carcinoma and its potential role in guiding treatment decisions.